Pfizer Inc. (NYSE:PFE) Shares Purchased by Disciplined Equity Management Inc.

Disciplined Equity Management Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 2,676.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 66,920 shares of the biopharmaceutical company’s stock after buying an additional 64,510 shares during the period. Pfizer makes up approximately 1.2% of Disciplined Equity Management Inc.’s holdings, making the stock its 14th largest holding. Disciplined Equity Management Inc.’s holdings in Pfizer were worth $1,857,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. OLD National Bancorp IN boosted its position in shares of Pfizer by 26.2% in the 3rd quarter. OLD National Bancorp IN now owns 200,937 shares of the biopharmaceutical company’s stock worth $6,665,000 after buying an additional 41,679 shares in the last quarter. Tompkins Financial Corp increased its stake in shares of Pfizer by 4.2% during the 3rd quarter. Tompkins Financial Corp now owns 39,236 shares of the biopharmaceutical company’s stock worth $1,301,000 after purchasing an additional 1,594 shares in the last quarter. Brown Shipley& Co Ltd raised its position in shares of Pfizer by 3.6% during the 3rd quarter. Brown Shipley& Co Ltd now owns 21,200 shares of the biopharmaceutical company’s stock worth $703,000 after purchasing an additional 746 shares during the last quarter. Comerica Bank lifted its stake in Pfizer by 42.6% in the 3rd quarter. Comerica Bank now owns 2,110,541 shares of the biopharmaceutical company’s stock valued at $70,007,000 after buying an additional 630,708 shares in the last quarter. Finally, Allen Mooney & Barnes Investment Advisors LLC acquired a new stake in Pfizer during the 3rd quarter valued at $1,124,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.1 %

Shares of PFE traded up $0.31 during trading hours on Thursday, hitting $28.66. The stock had a trading volume of 46,615,024 shares, compared to its average volume of 40,098,180. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80. The firm has a market cap of $162.40 billion, a P/E ratio of -475.42, a P/E/G ratio of 1.10 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The company’s fifty day simple moving average is $28.21 and its 200 day simple moving average is $27.71.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same period last year, the business posted $1.23 EPS. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.86%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday. Barclays upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Morgan Stanley lifted their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $35.69.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.